291 related articles for article (PubMed ID: 25483948)
1. The Fabry cardiomyopathy - diagnostic approach and current treatment.
Weidemann F; Ertl G; Wanner C; Krämer J
Curr Pharm Des; 2015; 21(4):473-8. PubMed ID: 25483948
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease and the heart.
Seydelmann N; Wanner C; Störk S; Ertl G; Weidemann F
Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):195-204. PubMed ID: 25987173
[TBL] [Abstract][Full Text] [Related]
3. The Fabry cardiomyopathy: models for the cardiologist.
Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
[TBL] [Abstract][Full Text] [Related]
4. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
5. [Cardiac involvement in Fabry's disease].
Weidemann F; Breunig F
Med Klin (Munich); 2008 Mar; 103(3):161-5. PubMed ID: 18344066
[TBL] [Abstract][Full Text] [Related]
6. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease.
Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
[TBL] [Abstract][Full Text] [Related]
9. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
10. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
11. [Heart involvement in Anderson-Fabry disease: Italian recommendations for diagnostic, follow-up and therapeutic management].
Pieruzzi F; Pieroni M; Zachara E; Marziliano N; Morrone A; Cecchi F
G Ital Cardiol (Rome); 2015 Nov; 16(11):630-8. PubMed ID: 26571477
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease--a primer for cardiologists.
Mursă A; Ginghină C; Jurcut R
Rom J Intern Med; 2014; 52(4):216-22. PubMed ID: 25726623
[TBL] [Abstract][Full Text] [Related]
13. Role of cardiac imaging in Anderson-Fabry cardiomyopathy.
Serra W; Marziliano N
Cardiovasc Ultrasound; 2019 Jan; 17(1):1. PubMed ID: 30674321
[TBL] [Abstract][Full Text] [Related]
14. Physiologic or pathologic hypertrophy: how can we know?
Lai EJ; Rakowski H
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):919-22. PubMed ID: 24972675
[TBL] [Abstract][Full Text] [Related]
15. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
17. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
Lui CY; Ju H
Am J Cardiol; 2006 Dec; 98(11):1557-8. PubMed ID: 17126672
[No Abstract] [Full Text] [Related]
18. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
[TBL] [Abstract][Full Text] [Related]
19. [The neurological manifestations of Fabry disease. A review].
Firsov KV; Kotov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
Kampmann C; Perrin A; Beck M
Orphanet J Rare Dis; 2015 Sep; 10():125. PubMed ID: 26416388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]